. . . "[3E90126A648C]" . "Positron emission tomography and clinical predictors of survival in primary extragonadal germ cell tumors" . . . . "extragonadal; germ cell; tumor; outcome"@en . "2"^^ . . "25" . "Positron emission tomography and clinical predictors of survival in primary extragonadal germ cell tumors"@en . . "Prim\u00E1rn\u00ED extragonad\u00E1ln\u00ED germin\u00E1ln\u00ED n\u00E1dory (EGT) jsou vz\u00E1cn\u00FDm n\u00E1dorem a tvo\u0159\u00ED p\u0159ibli\u017En\u011B 2\u20134 % v\u0161ech germin\u00E1ln\u00EDch n\u00E1dor\u016F dosp\u011Bl\u00FDch mu\u017E\u016F. Jejich progn\u00F3za je ve srovn\u00E1n\u00ED s prim\u00E1rn\u011B testikul\u00E1rn\u00EDmi germin\u00E1ln\u00EDmi n\u00E1dory kv\u016Fli relativn\u00ED chemorezistenci a zpravidla pokro\u010Dil\u00E9mu stadiu v dob\u011B diagn\u00F3zy hor\u0161\u00ED. C\u00EDlem na\u0161\u00ED studie bylo zhodnotit roli pozitronov\u00E9 emisn\u00ED tomografie s fluorodeoxygluk\u00F3zou (FDG-PET) jako prognostick\u00E9ho faktoru u nemocn\u00FDch s EGT. Pacienti a metody: Retrospektivn\u011B jsme analyzovali soubor 36 mu\u017E\u016F s prim\u00E1rn\u011B mediastin\u00E1ln\u00EDm nebo retroperitone\u00E1ln\u00EDm germin\u00E1ln\u00EDm n\u00E1dorem. Pacienti byli l\u00E9\u010Deni v letech 1994\u20132010. Pro stanoven\u00ED diagn\u00F3zy EGT jsme vy\u017Eadovali negativn\u00ED n\u00E1lez sonografick\u00E9ho vy\u0161et\u0159en\u00ED varlat a/nebo negativn\u00ED testikul\u00E1rn\u00ED biopsii. V\u0161ichni nemocn\u00ED byli l\u00E9\u010Deni chemoterapi\u00ED na b\u00E1zi platiny a resekovateln\u00E1 rezidu\u00E1ln\u00ED lo\u017Eiska byla odstran\u011Bna opera\u010Dn\u011B. V\u00FDsledky: Jednolet\u00E9 celkov\u00E9 p\u0159e\u017Eit\u00ED (OS) dos\u00E1hlo 81 % (95% interval spolehlivosti [CI]: 68\u201394 %) a t\u0159\u00EDlet\u00E9 OS 55 % (CI: 38\u201371 %). \u017D\u00E1dn\u00FD z pacient\u016F, kte\u0159\u00ED m\u011Bli pozitivn\u00ED n\u00E1lez na FDG-PET vy\u0161et\u0159en\u00ED po 1. linii chemoterapie, nep\u0159e\u017Eil t\u0159i roky po stanoven\u00ED diagn\u00F3zy. Jednolet\u00E9 a t\u0159\u00EDlet\u00E9 OS dos\u00E1hlo 69 % a 20 % u nemocn\u00FDch s pozitivn\u00EDmi markery a 90 % a 67 % u pacient\u016F s negativn\u00EDmi markery po chemoterapii 1. linie. Rovn\u011B\u017E negativn\u00ED v\u00FDsledek FDG-PET po ukon\u010Den\u00ED l\u00E9\u010Dby byl v\u00FDznamn\u00FD prognostick\u00FD parametr pro OS \u2013 z t\u011Bchto pacient\u016F 100 % p\u0159e\u017Eilo t\u0159i roky a 89 % p\u011Bt let od stanoven\u00ED diagn\u00F3zy. Z\u00E1v\u011Br: Negativn\u00ED v\u00FDsledek FDG-PET po chemoterapii 1. linie a tak\u00E9 po ukon\u010Den\u00ED syst\u00E9mov\u00E9 terapie a resekci rezidu\u00E1ln\u00EDch n\u00E1dorov\u00FDch lo\u017Eisek v\u00FDrazn\u011B koreluj\u00ED s dlouhodob\u00FDm p\u0159e\u017Eit\u00EDm u nemocn\u00FDch s EGT." . . . "3" . . . . . . "B\u00FCchler, Tom\u00E1\u0161" . "6"^^ . . . "Klinick\u00E1 onkologie" . "Positron emission tomography and clinical predictors of survival in primary extragonadal germ cell tumors" . "0862-495X" . "Abrh\u00E1mov\u00E1, Jitka" . "I, V" . "RIV/00064190:_____/12:#0000363!RIV13-MZ0-00064190" . "RIV/00064190:_____/12:#0000363" . "Prim\u00E1rn\u00ED extragonad\u00E1ln\u00ED germin\u00E1ln\u00ED n\u00E1dory (EGT) jsou vz\u00E1cn\u00FDm n\u00E1dorem a tvo\u0159\u00ED p\u0159ibli\u017En\u011B 2\u20134 % v\u0161ech germin\u00E1ln\u00EDch n\u00E1dor\u016F dosp\u011Bl\u00FDch mu\u017E\u016F. Jejich progn\u00F3za je ve srovn\u00E1n\u00ED s prim\u00E1rn\u011B testikul\u00E1rn\u00EDmi germin\u00E1ln\u00EDmi n\u00E1dory kv\u016Fli relativn\u00ED chemorezistenci a zpravidla pokro\u010Dil\u00E9mu stadiu v dob\u011B diagn\u00F3zy hor\u0161\u00ED. C\u00EDlem na\u0161\u00ED studie bylo zhodnotit roli pozitronov\u00E9 emisn\u00ED tomografie s fluorodeoxygluk\u00F3zou (FDG-PET) jako prognostick\u00E9ho faktoru u nemocn\u00FDch s EGT. Pacienti a metody: Retrospektivn\u011B jsme analyzovali soubor 36 mu\u017E\u016F s prim\u00E1rn\u011B mediastin\u00E1ln\u00EDm nebo retroperitone\u00E1ln\u00EDm germin\u00E1ln\u00EDm n\u00E1dorem. Pacienti byli l\u00E9\u010Deni v letech 1994\u20132010. Pro stanoven\u00ED diagn\u00F3zy EGT jsme vy\u017Eadovali negativn\u00ED n\u00E1lez sonografick\u00E9ho vy\u0161et\u0159en\u00ED varlat a/nebo negativn\u00ED testikul\u00E1rn\u00ED biopsii. V\u0161ichni nemocn\u00ED byli l\u00E9\u010Deni chemoterapi\u00ED na b\u00E1zi platiny a resekovateln\u00E1 rezidu\u00E1ln\u00ED lo\u017Eiska byla odstran\u011Bna opera\u010Dn\u011B. V\u00FDsledky: Jednolet\u00E9 celkov\u00E9 p\u0159e\u017Eit\u00ED (OS) dos\u00E1hlo 81 % (95% interval spolehlivosti [CI]: 68\u201394 %) a t\u0159\u00EDlet\u00E9 OS 55 % (CI: 38\u201371 %). \u017D\u00E1dn\u00FD z pacient\u016F, kte\u0159\u00ED m\u011Bli pozitivn\u00ED n\u00E1lez na FDG-PET vy\u0161et\u0159en\u00ED po 1. linii chemoterapie, nep\u0159e\u017Eil t\u0159i roky po stanoven\u00ED diagn\u00F3zy. Jednolet\u00E9 a t\u0159\u00EDlet\u00E9 OS dos\u00E1hlo 69 % a 20 % u nemocn\u00FDch s pozitivn\u00EDmi markery a 90 % a 67 % u pacient\u016F s negativn\u00EDmi markery po chemoterapii 1. linie. Rovn\u011B\u017E negativn\u00ED v\u00FDsledek FDG-PET po ukon\u010Den\u00ED l\u00E9\u010Dby byl v\u00FDznamn\u00FD prognostick\u00FD parametr pro OS \u2013 z t\u011Bchto pacient\u016F 100 % p\u0159e\u017Eilo t\u0159i roky a 89 % p\u011Bt let od stanoven\u00ED diagn\u00F3zy. Z\u00E1v\u011Br: Negativn\u00ED v\u00FDsledek FDG-PET po chemoterapii 1. linie a tak\u00E9 po ukon\u010Den\u00ED syst\u00E9mov\u00E9 terapie a resekci rezidu\u00E1ln\u00EDch n\u00E1dorov\u00FDch lo\u017Eisek v\u00FDrazn\u011B koreluj\u00ED s dlouhodob\u00FDm p\u0159e\u017Eit\u00EDm u nemocn\u00FDch s EGT."@en . "http://www.linkos.cz/files/klinicka-onkologie/170/3965.pdf" . "Positron emission tomography and clinical predictors of survival in primary extragonadal germ cell tumors"@en . "159926" . "CZ - \u010Cesk\u00E1 republika" . . "8"^^ .